Vishad Kumar, MD

Dr. Vishad Kumar earned a Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.), a Medical Doctorate in Internal Medicine, and a Doctorate in Neurology from King George’s Medical College at Lucknow University in India. After residency training in India, he completeda three year residency in neurology and a one year internship in internal medicine at the University of Tennessee in Memphis.

In addition to his research experience for the Department of Neurology and Psychiatry at Vanderbilt University, Dr. Kumar serves as a clinical assistant professor at UTHSC in Memphis. He is a Board-Certified Neurologist and treats the following. He is available to see patients, and all tests associated with an initial visit can be performed in-house at Semmes Murphey for optimal convenience

Dr. Vishad Kumar is married to Pushpa Kumar and has two sons, Rahul and Ashish.

Extracurricular Interests:

  • Natural Photography
  • Travelling
  • Reading

Professional Societies:

  • American Academy of Neurology
  • Tennessee Medical Association
  • Tennessee Academy of Neurology
  • American Association of Physicians of Indian Origin

Clinical Research Studies:

  • Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon ß 1a) in Patients with Relapsing-Remitting Multiple Sclerosis (2010)
  • A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed On Therapy (2010)
  • A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns versus Usual Care in High-Dose Interferon Treated Subjects (2006)
  • A Multicenter Open-Label Study to evaluate Different Dosage Regimens of Levodopa/DDC/Entacapone combination in Patients with Parkinson’s Disease who start to experience End-Of-Dose “Wearing-Off” Symptoms Novartis CCOM998-1A04
  • Effects of LU 53439 and Deprenyl on the Metabolism of Phenyethlamine (PEA) to Phenylacetic Acid (PAA) by MOA-B in Primate Brain (1996)
  • Role of Newer Antiepileptic Drugs in Patients of Intractable Epilepsy (1993)
  • Role of Ancillary Drugs in Treatment of Patients with Parkinsonism (1992)

Presentations:

  • Kar AM, Kumar V, Verma M, Shankar K. Platelet biogenic amines and aggregation in Thrombotic Stroke. 9th Annual Conference of Indian Academy of Neurosciences. Lucknow, February 1990.
  • Varma M, Kar AM, Nag D, Maheswari PK, Kumar V, Shankar K. Platelet norepinephrine efflux and aggregation in thrombotic stroke. 16th International Joint Conference on Stroke and Cerebral Circulation, San Francisco. Stroke. vol. 22:1, January 1991.

Disorders & Treatments

Additional Areas of Expertise

  • Parkinson’s Disease
  • Dementia
  • Multiple Sclerosis
  • Seizures
  • Pseudotumor Cerebri
  • Dystonia
  • Spasticity
  • Migraines

 

Locations

Request an Appointment